BioCryst Pharma (BCRX) Posts Q4 Loss of 16c/Share; Updates on Pipeline, FY15 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to BioCryst Pharma (BCRX) Posts Q4 Loss of 16c/Share; Updates on Pipeline, FY15 Outlook

BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results

February 18, 2015 6:55 AM EST

RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2014.

"We are proud of our 2014 achievements; most notably our successful completion of the BCX4161 OPuS-1 trial and the initiation of OPuS-2 for the treatment of hereditary angioedema, as well as our first U.S. regulatory approval of a BioCryst discovered drug,... More